NasdaqGS:CAPRBiotechs
Capricor Therapeutics (CAPR) Valuation After New Deramiocel Data And Upcoming PDUFA Milestone
Capricor Therapeutics (CAPR) recently drew investor attention after presenting new clinical data on its Duchenne muscular dystrophy therapy deramiocel and confirming an upcoming PDUFA decision date with regulators.
See our latest analysis for Capricor Therapeutics.
Those clinical updates and the confirmed PDUFA date come as momentum has been strong, with a 24.36% 30 day share price return and a very large 1 year total shareholder return that has built on multi year gains.
If you are looking...